Intradigm Corporation Company Profile

16:45 EDT 22nd September 2017 | BioPortfolio

Intradigm is developing siRNA-derived cancer therapeutics utilizing its proprietary RNAi technology. Intradigm has led the advancement of siRNA from the test tube to a potent, tissue-targeted, systemically active therapeutic class of gene specific inhibitors. The Company believes that it is the first to demonstrate consistent and reproducible siRNA activity in animal disease models through targeted formulations of siRNA for systemic administration. Based upon the Company’s unique technology and capabilities for developing systemic tissue targeted formulations of siRNA and its ability to achieve efficacy in clinically relevant animal disease models, Intradigm has established an impressive cancer therapeutic product development program with its lead product, ICS-283, now in advanced pre-clinical development.
The Company’s initial focus is on siRNA inhibition of the VEGF pathway targeted to the angiogenic neovasculature. The siRNA formulated product can be used for the treatment of many serious diseases that result from excessive and unwanted angiogenesis, such as colon cancer, lung cancer and many other solid tumors as well as other angiogenesis based diseases such as ocular neovascularization. Intradigm has utilized its proprietary TargeTranÔ technology to develop siRNA formulations which can be systemically delivered and specifically targeted to neovasculature. This targeted, specific sequence siRNA, utilizing innovative layered nanoparticle technology, has been successfully evaluated in several angiogenesis disease animal models with demonstrated efficacy. Intradigm has identified colon cancer as the first indication to evaluate for its systemically administered VEGF pathway siRNA and expects to file an IND within the next 12 months.

In addition to its therapeutic product focus, Intradigm has taken advantage of its portfolio of in vivo siRNA technologies to establish a target validation service business to


12115 Parklawn Drive, Suite K
United States of America


Phone: (301)984-0185
Fax: (301)984-0186 (301)984-0186

News Articles [69 Associated News Articles listed on BioPortfolio]

Intrinsic4D Inc. Announces Public Sale of Substantially all of the Assets of its Operating Subsidiary and Transfer to NEX

TORONTO, ONTARIO -- (Marketwired) -- 05/11/17 -- Intrinsic4D Inc. (the "Corporation") (TSX VENTURE: IFD) provides stakeholders with an update in relation to its financial status and solvency. Publi...

Savaria Announces Resignation of Director and Appointment of New Director

LAVAL, QUEBEC -- (Marketwired) -- 07/07/17 -- Savaria Corporation (TSX: SIS) ("Savaria" or the "Corporation"), one of North America's leaders in the accessibility industry, is pleased to announce th...

Ventripoint Announces Results of Annual Shareholders' Meeting and Grant of Options and DSUs

TORONTO, ONTARIO -- (Marketwired) -- 08/16/17 -- Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation") (TSX VENTURE: VPT) announces that at its Annual General Meeting on August 14, 2017 ...

NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation

REHOVOT, Israel, Sept. 12, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) diso...

Geron Corporation Reports First Quarter 2017 Financial Results and Recent Events

MENLO PARK, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the first quarter ended March 31, 2017 and recent events. First Quarter...

ADMA Biologics Stockholders Vote to Approve Acquisition of Certain Assets from Biotest Pharmaceuticals Corporation

RAMSEY, N.J., May 30, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) announced today that its stockholders voted to approve ADMA’s previously announced acquisition of certain asset...

International Stem Cell Corporation Reports Progress in Phase I Clinical Trial for Parkinson's Disease

CARLSBAD, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies...

International Stem Cell Corporation Announces Operating Results for the Quarter ended March 31, 2017

CARLSBAD, Calif., May 17, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) ( (“ISCO” or “the Company”), a California-based clinical st...

PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [171 Associated Companies listed on BioPortfolio]

Intradigm Corporation

Intradigm is developing siRNA-derived cancer therapeutics utilizing its proprietary RNAi technology. Intradigm has led the advancement of siRNA from the test tube to a potent, tissue-targeted, system...

Toshiba Corporation

Toshiba Medical Systems Corporation is a leading worldwide provider of medical diagnostic imaging systems and comprehensive medical solutions, such as CT, X-ray and vascular, ultr...

Bruker Daltonics

Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analy...

NEC Corporation of America

NEC Corporation of America (NEC) is a leading technology integrator providing solutions that improve the way people work and communicate. NEC delivers integrated Solutions for Soc...

Hot Spring Spas

Hot Spring Spas is the world’s leading brand of hot tubs and is sold through a network of more than 700 independent dealers throughout North America and 70 countries around t...

More Information about "Intradigm Corporation" on BioPortfolio

We have published hundreds of Intradigm Corporation news stories on BioPortfolio along with dozens of Intradigm Corporation Clinical Trials and PubMed Articles about Intradigm Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Intradigm Corporation Companies in our database. You can also find out about relevant Intradigm Corporation Drugs and Medications on this site too.

Quick Search

Relevant Topic

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Corporate Database Quicklinks

Searches Linking to this Company Record